Assessment of independent effect of olanzapine and risperidone on risk of diabetes among patients with schizophrenia: population based nested case-control study
Open accessAbstract
Objective : To quantify the association between olanzapine and diabetes. Design : Population based nested case-control study. Setting : United Kingdom based General Practice Research Database comprising 3.5 million patients followed between 1987 and 2000. Participants : 19 637 patients who had been diagnosed as having and treated for schizophrenia. 451 incident cases of diabetes were matched with 2696 controls. Main outcome measures : Diagnosis and treatment of diabetes. Results : Patients taking olanzapine had a significantly increased risk of developing diabetes than non-users of antipsychotics (odds ratio 5.8, 95% confidence interval 2.0 to 16.7) and those taking conventional antipsychotics (4.2, 1.5 to 12.2). Patients taking risperidone had a non-significant increased risk of developing diabetes than non-users of antipsychotics (2.2, 0.9 to 5.2) and those taking conventional antipsychotics (1.6, 0.7 to 3.8). Conclusion : Olanzapine is associated with a clinically important and significant increased risk of diabetes.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Olanzapine use is linked to a higher risk of type 2 diabetes.
“In addition, those taking olanzapine require greater monitoring because of an increase in risk of type 2 diabetes associated with this medication (88).”
From Psychosocial care for people with diabetes: a position statement of the American Diabetes Association (2016) · cites this paper as [88]
Taking second-generation (atypical) antipsychotics, such as olanzapine, is associated with an increase in risk of type 2 diabetes.
“In addition, those taking second-generation (atypical) antipsychotics, such as olanzapine, require greater monitoring because of an increase in risk of type 2 diabetes associated with this medication (418-420).”
From 5. Facilitating Positive Health Behaviors and Well-being to Improve Health Outcomes:<i>Standards of Care in Diabetes—2023</i> (2023) · cites this paper as [418]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Antipsychotic-induced weight gain: a comprehensive research synthesis
Allison, D. B., Mentore, J. L., Heo, M., Chandler, L. P., Cappelleri, J. C., Infante, M. C., & Weiden, P. J. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.11.1686 · Cited by 2,382 · see citing works
Weight gain as a risk factor for clinical diabetes mellitus in women
Colditz, G. A., Willett, W. C., Rotnitzky, A., & Manson, J. E. (1995) · Annals of Internal Medicine · doi:10.7326/0003-4819-122-7-199504010-00001 · Cited by 2,064 · see citing works
Logistic Regression: A Self-Learning Text.
Selvin, S., & Kleinbaum, D. G. (1996) · Journal of the American Statistical Association · doi:10.2307/2291427 · Cited by 1,628 · see citing works
The UK General Practice Research Database
Walley, T., & Mantgani, A. (1997) · The Lancet · doi:10.1016/s0140-6736(97)04248-7 · Cited by 624 · see citing works
Novel antipsychotics and new onset diabetes
Wirshing, D. A., Spellberg, B. J., Erhart, S. M., Marder, S. R., & Wirshing, W. C. (1998) · Biological Psychiatry · doi:10.1016/s0006-3223(98)00100-0 · Cited by 407 · see citing works
Valproate, lamotrigine, and insulin‐mediated risks in women with epilepsy
Isojärvi, J. I. T., Rättyä, J., Myllylä, V. V., Knip, M., Koivunen, R. M., Pakarinen, A., Tekay, A., & Tapanainen, J. S. (1998) · Annals of Neurology · doi:10.1002/ana.410430406 · Cited by 342 · see citing works
The General Practice Research Database
Wood, L., & Martínez, C. (2004) · Drug Safety · doi:10.2165/00002018-200427120-00004 · Cited by 330 · see citing works
Melkersson, K. I., Hulting, A., & Brismar, K. (2000) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v61n1006 · Cited by 300 · see citing works
THE METABOLIC EFFECTS OF EPINEPHRINE AND RELATED AMINES
Ellis, S. (1956) · Pharmacological Reviews · doi:10.1016/s0031-6997(25)06998-4 · Cited by 288 · see citing works
Meyer, J. M. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n0509 · Cited by 267 · see citing works
Antipsychotic drugs and heart muscle disorder in international pharmacovigilance: data mining study
Coulter, D. M., Bate, A., Meyboom, R. H. B., Lindquist, M., & Edwards, I. R. (2001) · BMJ · doi:10.1136/bmj.322.7296.1207 · Cited by 234 · see citing works
Accuracy of diagnosis of psychosis on general practice computer system.
Nazareth, I., King, M., Haines, A., Rangel, L., & Myers, S. (1993) · BMJ · doi:10.1136/bmj.307.6895.32 · Cited by 196 · see citing works
The General Practice Research Database. Scientific and Ethical Advisory Group
Lawson, D. H. (1998) · QJM · doi:10.1093/qjmed/91.6.445 · Cited by 176 · see citing works
Olanzapine-Induced Ketoacidosis With Diabetes Mellitus
Lindenmayer, J., & PATEL, R. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.9.1471 · Cited by 169 · see citing works
Pharmacologic treatment of schizophrenia
Kane, J. M. (1999) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00059-1 · Cited by 153 · see citing works
Phenothiazines and Diabetes in Hospitalized Women
Thonnard‐Neumann, E. (1968) · American Journal of Psychiatry · doi:10.1176/ajp.124.7.978 · Cited by 145 · see citing works
Melkersson, K. I., Hulting, A., & Brismar, K. (1999) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v60n1112 · Cited by 125 · see citing works
Holbrook, T. L., Barrett-Connor, E. L., & Wingard, D. L. (1989) · PubMed · Cited by 122 · see citing works
Hyperglycemia Associated With Olanzapine
Fertig, M. K., Brooks, V. G., Shelton, P. S., & English, C. W. (1998) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v59n1208c · Cited by 110 · see citing works
Olanzapine-Induced Glucose Dysregulation
Bettinger, T. L., Mendelson, S. C., Dorson, P. G., & Crismon, M. L. (2000) · Annals of Pharmacotherapy · doi:10.1345/aph.19327 · Cited by 104 · see citing works
Ober, S. K., Hudak, R., & Rusterholtz, A. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.6.970 · Cited by 93 · see citing works
Howarth, P. H., Mb, E., & Holgate, S. (1984) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1984.tb05013.x · Cited by 88 · see citing works
Diabetes as a result of atypical anti‐psychotic drugs – a report of three cases
Rigalleau, V., Gatta‐Cherifi, B., Bonnaud, S., Masson, M., Bourgeois, M.-L., Vergnot, V., & Gin, H. (2000) · Diabetic Medicine · doi:10.1046/j.1464-5491.2000.00296.x · Cited by 80 · see citing works
Effect of duration of low-dose oral contraceptive administration on carbohydrate metabolism
Wynn, V. (1982) · American Journal of Obstetrics and Gynecology · doi:10.1016/s0002-9378(16)32481-4 · Cited by 74 · see citing works
Biswas, P. N., Wilton, L., Pearce, G. L., Freemantle, S. N., & Shakir, S. (2001) · Journal of Psychopharmacology · doi:10.1177/026988110101500405 · Cited by 67 · see citing works
Goodall, E., Oxtoby, C., Richards, R. P., Watkinson, G., Brown, D., & Silversonte, T. (1988) · The British Journal of Psychiatry · doi:10.1192/bjp.153.2.208 · Cited by 61 · see citing works
Analysis of Matched Data Using Logistic Regression
Kleinbaum, D. G., & Klein, M. (2010) · Statistics for biology and health · doi:10.1007/978-1-4419-1742-3_11 · Cited by 48 · see citing works
Psychotropic drug induced weight gain: mechanisms and management.
Bernstein, J. G. (1988) · PubMed · Cited by 42 · see citing works
Pharmacotherapy of Type 2 Diabetes Mellitus
Rendell, M., & Kirchain, W. R. (2000) · Annals of Pharmacotherapy · doi:10.1345/aph.19171 · Cited by 30 · see citing works
Drugs of the Psychopharmacological Revolution in Clinical Psychiatry
Lieberman, J. A., Golden, R., Stroup, T. S., & McEvoy, J. P. (2000) · Psychiatric Services · doi:10.1176/appi.ps.51.10.1254 · Cited by 29 · see citing works
Analysis of Matched Data Using Logistic Regression
Kleinbaum, D. G. (1994) · Springer eBooks · doi:10.1007/978-1-4757-4108-7_8 · Cited by 9 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Consensus development conference on antipsychotic drugs and obesity and diabetes
American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, & North American Association for the Study of Obesity (2004) · Diabetes Care · doi:10.2337/diacare.27.2.596 · Cited by 1,554 · see citing works
Second-Generation (Atypical) Antipsychotics and Metabolic Effects
Newcomer, J. W. (2005) · CNS Drugs · doi:10.2165/00023210-200519001-00001 · Cited by 1,334 · see citing works
Schizophrenia and increased risks of cardiovascular disease
Hennekens, C. H., Hennekens, A. R., Hollar, D., & Casey, D. E. (2005) · American Heart Journal · doi:10.1016/j.ahj.2005.02.007 · Cited by 1,070 · see citing works
Young-Hyman, D., de Groot, M., Hill-Briggs, F., Gonzalez, J. S., Hood, K., & Peyrot, M. (2016) · Diabetes Care · doi:10.2337/dc16-2053 · Cited by 1,072 · see citing works
Mood disorders in the medically ill: scientific review and recommendations
Evans, D. L., Charney, D. S., Lewis, L., Golden, R. N., Gorman, J. M., Krishnan, K. R. R., Nemeroff, C. B., Bremner, J. D., Carney, R. M., Coyne, J. C., et al. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.05.001 · Cited by 1,071 · see citing works
Physical Health Monitoring of Patients With Schizophrenia
Marder, S. R., Essock, S. M., Miller, A. L., Buchanan, R. W., Casey, D. E., Davis, J. M., Kane, J. M., Lieberman, J. A., Schooler, N. R., Covell, N. H., et al. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.8.1334 · Cited by 812 · see citing works
Self-citationRelationship of depression to diabetes types 1 and 2: epidemiology, biology, and treatment
Musselman, D. L., Betan, E. J., Larsen, H., & Phillips, L. S. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(03)00569-9 · Cited by 670 · see citing works
Endocrine disrupters as obesogens
Grün, F., & Blumberg, B. (2009) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2009.02.018 · Cited by 586 · see citing works
Keck, P. E., Marcus, R. N., Tourkodimitris, S., Ali, M. W., Liebeskind, A., Saha, A. R., Ingenito, G. G., & Aripiprazole Study Group (2003) · American Journal of Psychiatry · doi:10.1176/appi.ajp.160.9.1651 · Cited by 501 · see citing works
American Diabetes Association Professional Practice Committee (2022) · Diabetes Care · doi:10.2337/dc22-s005 · Cited by 445 · see citing works
Modern antipsychotic drugs: a critical overview
Gardner, D. M. (2005) · Canadian Medical Association Journal · doi:10.1503/cmaj.1041064 · Cited by 422 · see citing works
Yatham, L. N., Kennedy, S. H., O'Donovan, C., Parikh, S., MacQueen, G., McIntyre, R., Sharma, V., Silverstone, P., Alda, M., Baruch, P., et al. (2005) · Bipolar Disorders · doi:10.1111/j.1399-5618.2005.00219.x · Cited by 388 · see citing works
ElSayed, N. A., Aleppo, G., Aroda, V. R., Bannuru, R. R., Brown, F. M., Bruemmer, D., Collins, B. S., Hilliard, M. E., Isaacs, D., Johnson, E. L., et al. (2023) · Diabetes Care · doi:10.2337/dc23-s005 · Cited by 362 · see citing works
Gelenberg, A. J. (2004) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v65n0101 · Cited by 356 · see citing works
Lewis, J. D., Bilker, W. B., Weinstein, R. B., & Strom, B. L. (2005) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1115 · Cited by 342 · see citing works
(2019) · Diabetes Care · doi:10.2337/dc20-s005 · Cited by 346 · see citing works
Falkai, P., Wobrock, T., Lieberman, J. A., Glenthoj, B. Y., Gattaz, W. F., Möller, H., & WFSBP Task Force on Treatment Guide (2006) · The World Journal of Biological Psychiatry · doi:10.1080/15622970500483177 · Cited by 331 · see citing works
Glucose Metabolism in Patients With Schizophrenia Treated With Atypical Antipsychotic Agents
Henderson, D. C., Cagliero, E., Copeland, P. M., Borba, C. P. C., Evins, A. E., Hayden, D. L., Weber, M., Anderson, E. J., Allison, D. B., Daley, T. B., et al. (2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.1.19 · Cited by 317 · see citing works
Introduction: Methods, Commentary, and Summary
Alexopoulos, G. S., Streim, J. E., Carpenter, D. P., & Docherty, J. P. (2004) · The Journal of Clinical Psychiatry · Cited by 316 · see citing works
The metabolic effects of antipsychotic medications
Newcomer, J. W., & Haupt, D. W. (2006) · The Canadian Journal of Psychiatry · doi:10.1177/070674370605100803 · Cited by 315 · see citing works
Long-Term Use of Antidepressants for Depressive Disorders and the Risk of Diabetes Mellitus
Andersohn, F., Schade, R., Suissa, S., & Garbe, E. (2009) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2008.08071065 · Cited by 315 · see citing works
American Diabetes Association (2021) · Diabetes Care · doi:10.2337/dc21-s005 · Cited by 299 · see citing works
Smith, M. J., Hopkins, D., Peveler, R., Holt, R. I. G., Woodward, M., & Ismail, K. (2008) · The British Journal of Psychiatry · doi:10.1192/bjp.bp.107.037184 · Cited by 274 · see citing works
Falkai, P., Wobrock, T., Lieberman, J. A., Glenthoj, B. Y., Gattaz, W. F., Möller, H., & WFSBP Task Force on Treatment Guide (2005) · The World Journal of Biological Psychiatry · doi:10.1080/15622970510030090 · Cited by 269 · see citing works
Metabolic side effects of antipsychotic medication
Tschoner, A., Engl, J., Laimer, M. W., Kaser, S., Rettenbacher, M. A., Fleischhacker, W. W., Patsch, J. R., & Ebenbichler, C. F. (2007) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2007.01416.x · Cited by 253 · see citing works
Adverse Metabolic Effects Associated with Atypical Antipsychotics
Melkersson, K. I., & Dahl, M. (2004) · Drugs · doi:10.2165/00003495-200464070-00003 · Cited by 245 · see citing works
Metabolic syndrome and mental illness.
Newcomer, J. W. (2007) · PubMed · Cited by 233 · see citing works
Gender-specific care of the patient with diabetes: review and recommendations
Legato, M. J., Gelzer, A., Goland, R., Ebner, S. A., Rajan, S., Villagra, V., & Kosowski, M. (2006) · Gender Medicine · doi:10.1016/s1550-8579(06)80202-0 · Cited by 225 · see citing works
Metabolic issues and cardiovascular disease in patients with psychiatric disorders
Casey, D. E. (2005) · The American Journal of Medicine Supplements · doi:10.1016/j.amjmed.2005.01.046 · Cited by 210 · see citing works
Atypical antipsychotics and glucose dysregulation: a systematic review
Jin, H., Meyer, J. M., & Jeste, D. V. (2004) · Schizophrenia Research · doi:10.1016/j.schres.2004.03.024 · Cited by 195 · see citing works
Minireview: The Case for Obesogens
Grün, F., & Blumberg, B. (2009) · Molecular Endocrinology · doi:10.1210/me.2008-0485 · Cited by 188 · see citing works
Higgins, J. P., Ramsay, C., Reeves, B. C., Deeks, J. J., Shea, B., Valentine, J. C., Tugwell, P., & Wells, G. (2013) · Research Synthesis Methods · doi:10.1002/jrsm.1056 · Cited by 183 · see citing works
American Diabetes Association (2018) · Diabetes Care · doi:10.2337/dc19-s004 · Cited by 183 · see citing works
Abnormal glucose metabolism in patients treated with antipsychotics
Scheen, A. J., & Hert, M. A. F. D. (2007) · Diabetes & Metabolism · doi:10.1016/j.diabet.2007.01.003 · Cited by 179 · see citing works
Ader, M., Kim, S. P., Catalano, K. J., Ionut, V., Hücking, K., Richey, J. M., Kabir, M., & Bergman, R. N. (2005) · Diabetes · doi:10.2337/diabetes.54.3.862 · Cited by 166 · see citing works
Minimising metabolic and cardiovascular risk in schizophrenia: diabetes, obesity and dyslipidaemia
Barnett, A. H., Mackin, P., Chaudhry, I. B., Farooqi, A. M., Gadsby, R., Heald, A. H., Hill, J., Millar, H. L., Peveler, R., Rees, A., et al. (2007) · Journal of Psychopharmacology · doi:10.1177/0269881107075509 · Cited by 166 · see citing works
Patients on Atypical Antipsychotic Drugs
Lean, M. E. J., & Pajonk, F. (2003) · Diabetes Care · doi:10.2337/diacare.26.5.1597 · Cited by 165 · see citing works
American Diabetes Association (2017) · Diabetes Care · doi:10.2337/dc18-s003 · Cited by 171 · see citing works
Coccurello, R., & Moles, A. (2010) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2010.04.008 · Cited by 146 · see citing works
Schizophrenia, the metabolic syndrome and diabetes
Holt, R. I. G., Peveler, R., & Byrne, C. D. (2004) · Diabetic Medicine · doi:10.1111/j.1464-5491.2004.01199.x · Cited by 139 · see citing works
The cardiovascular and respiratory health of people with schizophrenia
Filik, R., Sipos, A., Kehoe, P. G., Burns, T., Cooper, S. J., Stevens, H., Laugharne, R., Young, G., Perrington, S., McKendrick, J., et al. (2006) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2006.00768.x · Cited by 134 · see citing works
The Atypical Antipsychotic Therapy and Metabolic Issues National Survey
Newcomer, J. W., Nasrallah, H. A., & Loebel, A. D. (2004) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000142281.85207.d5 · Cited by 133 · see citing works
Atypical Antipsychotics and Metabolic Dysregulation
Nasrallah, H. A., & Newcomer, J. W. (2004) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000142282.62336.e9 · Cited by 132 · see citing works
Meyer, R. E., Salzman, C., Youngstrom, E. A., Clayton, P. J., Goodwin, F. K., Mann, J. J., Alphs, L. D., Broich, K., Goodman, W. K., Greden, J. F., et al. (2010) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.10cs06070blu · Cited by 129 · see citing works
Self-citationDifferential metabolic effects of antipsychotic treatments
Haupt, D. W. (2006) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2006.06.003 · Cited by 129 · see citing works
Cardiometabolic effects of psychotropic medications
Abosi, O. J., Lopes, S., Schmitz, S. L., & Fiedorowicz, J. G. (2018) · Hormone Molecular Biology and Clinical Investigation · doi:10.1515/hmbci-2017-0065 · Cited by 128 · see citing works
Antipsychotic-Induced Type 2 Diabetes: Evidence From a Large Health Plan Database
Gianfrancesco, F. D., White, R., Wang, R., & Nasrallah, H. A. (2003) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000085404.08426.3a · Cited by 126 · see citing works
Metabolic risk during antipsychotic treatment
Newcomer, J. W. (2004) · Clinical Therapeutics · doi:10.1016/j.clinthera.2004.12.003 · Cited by 125 · see citing works
Briggs, A., Wild, D., Lees, M., Reaney, M., Dursun, S., Parry, D., & Mukherjee, J. (2008) · Health and Quality of Life Outcomes · doi:10.1186/1477-7525-6-105 · Cited by 122 · see citing works
A Comparison of Type 2 Diabetes Outcomes Among Persons With and Without Severe Mental Illnesses
Dixon, L. B., Kreyenbuhl, J. A., Dickerson, F., Donner, T. W., Brown, C. H., Wolheiter, K., Postrado, L. T., Goldberg, R. W., Fang, L., Marano, C. M., et al. (2004) · Psychiatric Services · doi:10.1176/appi.ps.55.8.892 · Cited by 115 · see citing works
Self-citationRisk for coronary heart disease in people with severe mental illness
Osborn, D., Nazareth, I., & King, M. (2006) · The British Journal of Psychiatry · doi:10.1192/bjp.bp.104.008060 · Cited by 117 · see citing works
Hyperglycemia and Diabetes in Patients With Schizophrenia or Schizoaffective Disorders
Cohen, D., Stolk, R. P., Grobbee, D. E., & Wied, C. C. G. (2006) · Diabetes Care · doi:10.2337/diacare.29.04.06.dc05-1261 · Cited by 115 · see citing works
Off-label psychopharmacologic prescribing for children: History supports close clinical monitoring
ZITO, J. M., Derivan, A., Kratochvil, C. J., Safer, D. J., Fegert, J. M., & Greenhill, L. L. (2008) · Child and Adolescent Psychiatry and Mental Health · doi:10.1186/1753-2000-2-24 · Cited by 114 · see citing works
Lambert, B. L., Cunningham, F. E., Miller, D. R., Dalack, G. W., & Hur, K. (2006) · American Journal of Epidemiology · doi:10.1093/aje/kwj289 · Cited by 112 · see citing works
Citrome, L., Jaffe, A. B., Levine, J., Allingham, B., & Robinson, J. (2004) · Psychiatric Services · doi:10.1176/appi.ps.55.9.1006 · Cited by 111 · see citing works
Abnormalities of glucose metabolism associated with atypical antipsychotic drugs.
Newcomer, J. W. (2004) · PubMed · Cited by 109 · see citing works
Yood, M. U., DeLorenze, G. N., Quesenberry, C. P., Oliveria, S. A., Tsai, A., Willey, V. J., McQuade, R. D., Newcomer, J. W., & L'Italien, G. J. (2009) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1781 · Cited by 103 · see citing works
Self-citationMelkersson, K. I., & Dahl, M. (2003) · Psychopharmacology · doi:10.1007/s00213-003-1529-4 · Cited by 103 · see citing works
3. Comprehensive Medical Evaluation and Assessment of Comorbidities
American Diabetes Association (2016) · Diabetes Care · doi:10.2337/dc17-s006 · Cited by 101 · see citing works
Stephens, R. J., Bassel, C., & Sandor, P. (2004) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/1044546041648959 · Cited by 102 · see citing works
Clinicians' recognition of the metabolic adverse effects of antipsychotic medications
Buckley, P. F., Miller, D. D., SINGER, B., ARENA, J., & Stirewalt, E. (2005) · Schizophrenia Research · doi:10.1016/j.schres.2005.04.010 · Cited by 102 · see citing works
Schizophrenia: who is at risk? Who is a case?
Verdoux, H., & Cougnard‐Grégoire, A. (2006) · International Clinical Psychopharmacology · doi:10.1097/01.yic.0000201496.23259.85 · Cited by 102 · see citing works
Use and Safety of Antipsychotics in Behavioral Disorders in Elderly People With Dementia
Gareri, P., Fazio, P. D., Manfredi, V. G. L., & Sarro, G. D. (2013) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e3182a6096e · Cited by 101 · see citing works
Modelling estimates of the burden of respiratory syncytial virus infection in children in the UK
Taylor, S., Taylor, R. J., Lustig, R. L., Schuck‐Paim, C., Haguinet, F., Webb, D. J., Logie, J. W., Matias, G., & Fleming, D. (2016) · BMJ Open · doi:10.1136/bmjopen-2015-009337 · Cited by 99 · see citing works
Guo, J. J., Keck, P. E., Corey‐Lisle, P. K., Li, H., Jiang, D., Jang, R., & L'Italien, G. J. (2006) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v67n0707 · Cited by 91 · see citing works
Self-citationEffects of Olanzapine and Haloperidol on the Metabolic Status of Healthy Men
Vidarsdóttir, S., van Weenen, J. E. D. L., Frölich, M., Roelfsema, F., Romijn, J. A., & Pijl, H. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-1815 · Cited by 91 · see citing works
Bernardo, M., Rico‐Villademoros, F., García‐Rizo, C., Rojo, R., & Gómez‐Huelgas, R. (2021) · Advances in Therapy · doi:10.1007/s12325-021-01689-8 · Cited by 87 · see citing works
Kelly, D. L., Conley, R. R., & Carpenter, W. T. (2005) · Drugs · doi:10.2165/00003495-200565080-00006 · Cited by 87 · see citing works
Lublin, H., Eberhard, J., & Levander, S. E. (2005) · International Clinical Psychopharmacology · doi:10.1097/00004850-200507000-00001 · Cited by 87 · see citing works
Ban, L., Sprigg, N., Sultan, A. A., Nelson‐Piercy, C., Bath, P. M., Ludvigsson, J. F., Stephansson, O., & Tata, L. J. (2017) · Journal of the American Heart Association · doi:10.1161/jaha.116.004601 · Cited by 86 · see citing works
Racial Disparity in the Pharmacological Management of Schizophrenia
Kreyenbuhl, J. A., ZITO, J. M., Buchanan, R. W., Soeken, K. L., & Lehman, A. F. (2003) · Schizophrenia Bulletin · doi:10.1093/oxfordjournals.schbul.a006996 · Cited by 81 · see citing works
Self-citationMortimer, A. M., Martin, S. D., Löo, H., & Peuskens, J. (2004) · International Clinical Psychopharmacology · doi:10.1097/00004850-200403000-00002 · Cited by 81 · see citing works
Belgian consensus on metabolic problems associated with atypical antipsychotics
Nayer, A. D., Hert, M. D., Scheen, A. J., Gaal, L. V., Peuskens, J., & on behalf of the Consensus Group (2005) · International Journal of Psychiatry in Clinical Practice · doi:10.1080/13651500510018310 · Cited by 80 · see citing works
Long-Term Changes in Weight and Plasma Lipids during Maintenance Treatment with Ziprasidone
Weiden, P. J., Newcomer, J. W., Loebel, A. D., Yang, R., & Lebovitz, H. E. (2007) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301482 · Cited by 79 · see citing works
Ramaswamy, K., Masand, P. S., & Nasrallah, H. A. (2006) · Annals of Clinical Psychiatry · doi:10.1080/10401230600801234 · Cited by 77 · see citing works
Risk of weight gain for specific antipsychotic drugs: a meta-analysis
Spertus, J. V., Horvitz-Lennon, M. V., Abing, H. K., & Normand, S. T. (2018) · Schizophrenia · doi:10.1038/s41537-018-0053-9 · Cited by 77 · see citing works
Antipsychotics and Diabetes: An Age-Related Association
Hammerman, A., Dreiher, J., Klang, S. H., Munitz, H., Cohen, A. D., & Goldfracht, M. (2008) · Annals of Pharmacotherapy · doi:10.1345/aph.1l015 · Cited by 75 · see citing works
Diabetes, Psychiatric Disorders, and the Metabolic Effects of Antipsychotic Medications
Llorente, M. D., & Urrutia, V. (2006) · Clinical Diabetes · doi:10.2337/diaclin.24.1.18 · Cited by 75 · see citing works
Ruiz, J. S., García, J. B., Ruiloba, J. V., Ubago, J. G., & González, M. P. G.-P. (2008) · Actas Españolas de Psiquiatría · Cited by 74 · see citing works
Association between antipsychotic drugs and diabetes
Holt, R. I. G., & Peveler, R. (2005) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2005.00495.x · Cited by 73 · see citing works
Testing for diabetes in hospitalised patients prescribed antipsychotic drugs
Taylor, D. M., Young, C., Esop, R., Paton, C., & Walwyn, R. E. A. (2004) · The British Journal of Psychiatry · doi:10.1192/bjp.185.2.152 · Cited by 73 · see citing works
Fuller, M. A., Shermock, K. M., Secic, M., & Grogg, A. L. (2003) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.23.8.1037.32876 · Cited by 73 · see citing works
Comparative Tolerability of Dopamine D2/3 Receptor Partial Agonists for Schizophrenia
Keks, N. A., Hope, J., Schwartz, D., McLennan, H., Copolov, D., & Meadows, G. N. (2020) · CNS Drugs · doi:10.1007/s40263-020-00718-4 · Cited by 71 · see citing works
Monster, T. B. M., Johnsen, S. P., Olsen, M. L., McLaughlin, J. K., & Sørensen, H. T. (2004) · The American Journal of Medicine · doi:10.1016/j.amjmed.2004.06.027 · Cited by 71 · see citing works
Antipsychotics and diabetes: review of non-prospective data
Haddad, P. M. (2004) · British Journal of Psychiatry · doi:10.1192/bjp.184.47.s80 · Cited by 71 · see citing works
Smith, R. C., Lindenmayer, J., Bark, N. M., Warner‐Cohen, J., Vaidhyanathaswamy, S., & Khandat, A. (2005) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145705005110 · Cited by 70 · see citing works
Antipsychotic Medication Use Among Children and Risk of Diabetes Mellitus
Andrade, S. E., Lo, J. C.-M., Roblin, D. W., Fouayzi, H., Connor, D. F., Penfold, R. B., Chandra, M., Reed, G. W., & Gurwitz, J. H. (2011) · PEDIATRICS · doi:10.1542/peds.2011-0855 · Cited by 70 · see citing works
Tidemalm, D., Waern, M., Stefansson, C.-G., Elofsson, S., & Runeson, B. (2008) · Clinical Practice and Epidemiology in Mental Health · doi:10.1186/1745-0179-4-23 · Cited by 68 · see citing works
Bushe, C., & Leonard, B. E. (2004) · The British Journal of Psychiatry · doi:10.1192/bjp.184.47.s87 · Cited by 68 · see citing works
Update on Psychotropic Medication Use in Renal Disease
Cohen, L. M., Tessier, E. G., Germain, M. J., & Levy, N. B. (2004) · Psychosomatics · doi:10.1176/appi.psy.45.1.34 · Cited by 65 · see citing works
Treatment of Schizophrenia With Long-Acting Fluphenazine, Haloperidol, or Risperidone
Olfson, M., Marcus, S. C., & Ascher‐Svanum, H. (2006) · Schizophrenia Bulletin · doi:10.1093/schbul/sbm033 · Cited by 65 · see citing works
Antipsychotic drugs and diabetes—an application of the Austin Bradford Hill criteria
Holt, R. I. G., & Peveler, R. (2006) · Diabetologia · doi:10.1007/s00125-006-0279-3 · Cited by 65 · see citing works
Risk of Treatment-Emergent Diabetes Mellitus in Patients Receiving Antipsychotics
Citrome, L. L., Holt, R. I., Zachry, W. M., Clewell, J. D., Orth, P. A., Karagianis, J. L., & Hoffmann, V. P. (2007) · Annals of Pharmacotherapy · doi:10.1345/aph.1k141 · Cited by 64 · see citing works
Reist, C., Mintz, J., Albers, L. J., Jamal, M. M., Szabó, S., & Özdemir, V. (2007) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31802e5126 · Cited by 64 · see citing works
Olié, J., Spina, E., Murray, S., & Yang, R. (2006) · International Clinical Psychopharmacology · doi:10.1097/01.yic.0000182121.59296.70 · Cited by 64 · see citing works
Weight gain and new onset diabetes associated with olanzapine and risperidone
Farwell, W. R., Stump, T. E., Wang, J., Tafesse, E., L'Italien, G. J., & Tierney, W. M. (2004) · Journal of General Internal Medicine · doi:10.1111/j.1525-1497.2004.40126.x · Cited by 64 · see citing works
Self-citationPhysiogenomic comparison of weight profiles of olanzapine- and risperidone-treated patients
Ruaño, G., Goethe, J. W., Caley, C. F., Woolley, S. B., Holford, T. R., Kocherla, M., Windemuth, A., & de León, J. (2007) · Molecular Psychiatry · doi:10.1038/sj.mp.4001944 · Cited by 63 · see citing works
Sleep-Related Eating Disorder Induced by Risperidone
Lu, M., & Shen, W. W. (2004) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v65n0220a · Cited by 60 · see citing works
Relationship of Atypical Antipsychotics with Development of Diabetes Mellitus
Citrome, L., & Jaffe, A. B. (2003) · Annals of Pharmacotherapy · doi:10.1345/aph.1d142 · Cited by 60 · see citing works
Dose Response and Atypical Antipsychotics in Schizophrenia
Kinon, B. J., AHL, J. S. B., Stauffer, V. L., Hill, A. L., & Buckley, P. F. (2004) · CNS Drugs · doi:10.2165/00023210-200418090-00005 · Cited by 59 · see citing works
- Authors
- Koro, C. E., Fedder, D. O., L'Italien, G. J., Weiss, S., Magder, L., Kreyenbuhl, J., Revicki, D., & Buchanan, R.
- Affiliations
- University of Maryland, Baltimore (US)
- Corresponding author
- Koro, Carol E
- ORCID
- Kreyenbuhl, Julie
- Venue
- BMJ
- Publisher
- BMJ
- Published
- 2002-08-03
- Volume
- 325
- Issue
- 7358
- Pages
- 243
- ISSN
- 0007-1447 (ISSN-L)
- 0959-8138
- 1468-5833
- PMC
- PMC117636
- OpenAlex
- W2160802754
- Cited by
- 421
- References
- 30
- Citations by year
- 2026: 3 · 2025: 6 · 2024: 4 · 2023: 4 · 2022: 5 · 2021: 8 · 2020: 6 · 2019: 3 · 2018: 7 · 2017: 8 · 2016: 8 · 2015: 8 · 2014: 5 · 2013: 10 · 2012: 9
- FWCI
- 37.10
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.bmj.com/company/legal-information/terms-conditions/legal-information/tdm-licencepolicy (tdm)
- Locations
- BMJ (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Health Sciences › Medicine › Pharmacology › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Neurology › Parkinson's Disease Mechanisms and Treatments
- Keywords
- olanzapine, risperidone, schizophrenia, diabetes risk, antipsychotic drugs, adverse drug reactions, typical antipsychotics, type 2 diabetes
- MeSH terms
- Olanzapine, Adult, Aged, Benzodiazepines, Diabetes Mellitus, Female, Follow-Up Studies, Humans, Male, Middle Aged, Pirenzepine, Regression Analysis, Risk Factors, Schizophrenia, Antipsychotic Agents, Cohort Studies, Odds Ratio, Case-Control Studies, Risperidone
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
